Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSATR-258 is a GRK-biased agonist of the β2-adrenergic receptor (β2-AR).1 It binds to the orthosteric site on β2-AR and mediates glucose uptake dependent on G protein-coupled receptor kinase 2 (GRK2) with low Gαs-dependent cAMP generation in a phenotypic screen. ATR-258 (10 µM) increases glucose uptake in L6 cells that endogenously express β2-AR, an effect that can be blocked by the β2-AR antagonist ICI 118551 (Item No. 15591) or the mTORC2 inhibitor JR-AB2-011. Oral administration of ATR-258 (0.3 mg/kg) improves glucose tolerance, reduces fat mass, and increases lean mass in diet-induced obese (DIO) mice without increasing heart weight. ATR-258 in combination with liraglutide (Item No. 24727) reduces fat mass without reducing lean mass in DIO mice.
WARNING This product is not for human or veterinary use.
1. GRK-